Abstract | Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-smallcell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease. Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-positive (ALK+) NSCLC in association with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clinical use in this molecularly defined subgroup of lung cancer. Many new ALK inhibitors are being developed and understanding the challenges of determining and addressing the adverse effects that are likely to be ALK specific, while maximizing the time of benefit on targeted agents, and understanding the mechanisms that underlie drug resistance will be critical in the future for informing the optimal therapy of ALK+ NSCLC.
Introduction
The anaplastic lymphoma kinase (ALK) gene was first identified in its aberrant, disease-causing form in 1989. 1 A reciprocal translocation between chromosomes 2 and 5 (t [2;5] [p23;q35]) had been noted in a subset of patients with anaplastic large-cell lymphomas. 1 Later, this aberration was proven to generate a fusion gene combining the 5' end of nucleophosmin (NPM) with the 3' kinase encoding region of a novel gene, subsequently named ALK. 2 However, it is the potential of aberrant ALK to act as an oncogene in many different cancers, especially non-small-cell lung cancer (NSCLC) that has heightened interest in ALK as a therapeutic target (Box 1). 3 In 2011, on the basis of dramatic and prolonged objective responses, the FDA approved crizotinib as the first licensed ALK inhibitor for ALK-positive (ALK+) NSCLC, effectively defining the relevance of a disease subtype in lung cancer by its response to a targeted therapy. 4, 5 Despite the early successes of crizotinib, it is clear that many challenges remain for those who treat, or are affected by, ALK+ NSCLC. This Review examines both what we already know and the major emerging questions associated with optimal management of this disease.
The biology of native ALK
ALK is located on chromosome 2 and encodes a transmembrane receptor tyrosine kinase that forms part of the insulin receptor superfamily, and has homology to the leukocyte tyrosine kinase. 6, 7 Expression of native ALK in adult human tissues seems to be restricted to the small intestine, testes and nervous system. 2 In mice, expression of ALK in parts of the embryonic and neonatal central and peripheral nervous systems suggests a role in neurological development. [6] [7] [8] In Drosophila, ALK has a proven role in the development of both the visual system and in visceral muscle patterning. [9] [10] [11] [12] [13] As with many other transmembrane tyrosine kinases, dimerisation is thought to mediate the normal activation of the receptor. 14 
Activating ALK in NSCLC
Although primary activating mutations in ALK do occur, in most ALK+ cancers, including NSCLC, activation of ALK is through the formation of fusion genes (Box 1 and Figure 1 ). [15] [16] [17] [18] [19] [20] Multiple 5' fusion partners for ALK occur in different ALK+ cancers. 20 In NSCLC, the dominant 5' fusion partner is EML4, but other rarer partners, notably KIF5B and TFG have been described. 3, 21, 22 All 5' fusion partners in oncogenic ALK rearrangements share certain key characteristics (Box 1). The 5' partner and its associated promoter are known to influence both the expression levels and sometimes the subcellular location of the fusion protein. 23, 24 Whether such variability introduces significant biological differences in terms of the downstream consequences of ALK activation is currently unclear.
Given the lack of association with smoking, tobaccorelated carcinogens are unlikely to underlie the aetiology of most ALK+ lung cancers. Although a number of general risk factors for non-smoking-related lung cancer have previously been identified, including radon gas, no molecularly categorized epidemiological studies have been undertaken to explore the role of such factors specifically in ALK+ disease. 31 The impact of ALK positivity on prognosis has been explored in studies of patients with early stage cancers post-resection, where both better and worse survival outcomes compared to ALK-negative groups have been reported. [32] [33] [34] [35] In the advanced-disease setting, ALK positivity seems to be associated with a neutral or slightly better prognosis compared with EGFR and ALK wildtype control groups. [36] [37] [38] However, although patients in these trials were crizotinib naive, many received pemetrexed within these studies (52-67%), a cytotoxic drug that has since been recognized to be particularly active in ALK+ NSCLC. 39, 40 Consequently, we may never know the true prognostic value of ALK positivity in the absence of any key treatment in this setting.
The time to disease progression of patients with advanced-stage ALK+ NSCLC treated with most platinumbased first-line combination therapies seems to be similar for both EGFR mutant and EGFR and ALK wild-type patients. 29 Time to progression and response to erlotinib are comparable to those seen in patients with wild-type EGFR and ALK but significantly lower than in patients with mutant EGFR. 29 By contrast, pemetrexed, a multitargeted antifolate chemotherapy, has prominent activity in ALK+ NSCLC. Among NSCLC patients treated with pemetrexed as monotherapy and combination therapy in different lines of therapy, the median progressionfree survival (PFS) in ALK+ patients was 9 months (range 1.5-21 months), compared to 4 months (range 1-12.5 months) in an EGFR, ALK and KRAS wild-type control group. 39 Within a multivariate analysis that adjusted for line of therapy, monotherapy versus platinum and non-platinum combination therapy, age, sex, histology and smoking status, only ALK positivity was associated with a lower risk of progression for those receiving pemetrexed (hazard ratio [HR] = 0.36; 95% CI 0.17-0.73; P = 0.0051). 39 In addition, ALK positivity is associated with a significantly higher response rate to pemetrexed (46.7%) than that seen in EGFR mutant or a double negative (that is, EGFR and KRAS wild type) control group (4.7% and 16.7%, respectively; P = 0.001). 40 Two initial hypotheses have been raised to explain the 'super-sensitivity' of ALK+ NSCLC to pemetrexed. Firstly, ALK positivity is associated with lower levels of thymidylate synthase, one of the targets of pemetrexed. 40 Secondly, ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase), a bifunctional enzyme that catalyses the last two steps of purine biosynthesis may be both a substrate for ALK-mediated phosphorylation (increasing the cells dependence upon this pathway) and a direct target for pemetrexed. 39 Whether this apparent activity will affect the outcomes of the ongoing confirmatory Key points ■ Crizotinib shows significant benefit in terms of both radiographic response and progression-free survival in ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) ■ Crizotinib is generally well tolerated and associated with common mild adverse effects such as gastrointestinal disturbance, visual changes, and low testosterone, as well as rare serious adverse effects such as transaminitis ■ Crizotinib resistance occurs through multiple different mechanisms including mutations and copy number gain that preserve ALK dominance, and the emergence of other oncogenic drivers that may weaken ALK dominance ■ In addition to a change in the biology of the cancer, cases of isolated central nervous system (CNS) progression on crizotinib could reflect inadequate CNS drug penetration ■ Newer ALK inhibitors, HSP90 inhibitors and pemetrexed have shown preclinical or clinical activity in ALK+ NSCLC and are being investigated further in patients with crizotinib resistant and crizotinib-naive ALK+ disease ■ The potential of these new agents to show activity in patients with CNS disease or crizotinib resistance will be critical to determine their roles in the management of ALK+ NSCLC randomized studies in patients with advanced-stage ALK+ NSCLC comparing crizotinib to either pemetrexed or docetaxel in the second-line setting (PROFILE 1007), 41 or to a platinum-pemetrexed doublet in the first-line setting (PROFILE 1014) 42 remains to be seen. Additional studies will also be required to determine if pemetrexed should now be prioritized as a cytotoxic agent for patients with metastatic ALK+ NSCLC who do not have access to crizotinib, after treatment failure following crizotinib, and/or in the locally advanced, adjuvant or neoadjuvant setting, either with or without concurrent radiation therapy.
ALK positivity seems to be associated with a particular pattern of metastatic spread. At the time of Box 1 | ALK activation in NSCLC and other cancers ALK is a tyrosine kinase primarily involved in developmental processes. It is expressed at low levels in adults, mainly in the gut, testes and nervous system, where its normal function remains under investigation. 20 ALK activation has been described in a number of different cancers including subsets of non-Hodgkin lymphoma, inflammatory myofibroblastic tumours, rhabdomyosarcomas, NSCLC, renal cancer, anaplastic thyroid cancers and neuroblastomas. [15] [16] [17] [18] [19] [20] 92, 93 In cancers arising from tissues in which full-length ALK is normally expressed, or, conceivably, where it becomes re-expressed during malignant dedifferentiation, oncogenic activation may involve point mutations in the ALK kinase domain (for example, neuroblastoma and anaplastic thyroid cancer). [15] [16] [17] [18] [19] However, in most tumours, including NSCLC, in order for ALK to function as an oncogenic driver, gene fusions that can induce both de novo ALK expression and activation are required. Multiple different 5' fusion partners for oncogenic ALK exist in different cancers that all share the following characteristics: a promoter region that is functional in the tissue of interest, and an encoded region capable of mediating oligomerisation of the fusion protein, which activates the ALK kinase domain in a manner comparable to the ligand-mediated oligomerisation of native ALK. 20 In addition, there are key structural constraints that must be met in both the 5' partner and the specific breakpoint selected in the gene for the resulting fusion protein to be stable. While tissue-specific expression of the 5' partner could influence the preferred fusion partners seen in some ALK-positive malignancies, in many cases the 5' partners represent very widely expressed proteins. Therefore, why EML4 is the dominant fusion partner in NSCLC, and not, for example, clathrin heavy chain (a ubiquitously expressed endocytic scaffold protein) or other very commonly expressed genes that have been reported as 5' partners in other ALK-positive malignancies, remains unknown. 94, 95 Abbreviation: NSCLC, non-small-cell lung cancer.
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diagnosis of metastatic disease, ALK+ patients, but not those with EGFR or KRAS mutations, were associated with a higher incidence of pericardial (odds ratio 4.61; P = 0.02) and pleural spread (odds ratio 4.8; P <0.001) than a triple-negative control group. 43 The incidence of hepatic disease in ALK+ and EGFR mutant patients was also significantly higher than in the control group (odds ratio 5.5; P = 0.003). 43 
Early success of crizotinib studies
Crizotinib is a small-molecule, orally bioavailable tyrosine kinase inhibitor (TKI) of both ALK and MET. 44 Within the first-in-man study of crizotinib, a series of molecularly defined expanded cohorts were recruited and treated at the recommended phase II dose of 250 mg twice daily for patients whose tumours were prescreened for evidence of either ALK or MET activation. 4 In addition to its activity in ALK+ NSCLC, clinical benefit of crizotinib has also been documented in both ALK+ lymphomas and sarcomas and in MET-positive NSCLC and oesophageal carcinomas. [45] [46] [47] [48] ALK positivity within all of the initial studies was determined using break-apart fluorescence in situ hybridization techno logy (Box 3). In the most recent NSCLC dataset from the phase I study, which included 119 patients of whom 116 were assessable for response, the objective response rate was 61%. 49 The high response rate was largely independent of age, sex, performance status or line of therapy. Median PFS was 10 months and although median overall survival data are not yet mature, the estimated overall survival rates at 6 months and 12 months were 90% and 81%, respectively. 49 Very similar results were obtained from the 136 patients with ALK+ tumours treated within the PROFILE 1005 single-arm, phase II study. 5 Within this study, evidence from patient reported outcomes showed significant and sustained symptomatic benefit in pain, dyspnoea, cough and fatigue after 6 weeks of crizotinib therapy. 5 Although crizotinib received accelerated approval in the USA in August 2011, this approval is conditional on the results of ongoing randomized studies comparing crizotinib to standard chemotherapies (PROFILE 1014 and 1007). 41, 42 In both of these studies, patients randomized to the chemotherapy arm will have the option of crossing over to crizotinib on disease progression. Consequently, the primary end point for both trials is PFS and not overall survival. A prospective study that could formally address the effect of crizotinib on overall survival in patients with advancedstage ALK+ NSCLC is unlikely to occur. However, Activation of ALK signalling is rare in most adult tissues but it is active in the development of the gut and nervous system. Activation of native ALK is via ligand-induced dimerisation and resultant autophosphorylation. In Drosophila the ligand for ALK is Jelly Belly, whereas in mammals pleiotrophin and midkine have been reported as ligands for ALK. 11, 12, 87, 88 In most ALK-positive cancers, ALK expression is re-instituted through the active promoter of a 5' partner that fuses with the kinase-encoding region of ALK. The resulting fusion gene then generates a fusion protein that can dimerise via domains in the 5' partner, mimicking ligand-induced activation.
14 Rarely, mutations in the kinase domain of full length ALK can also promote primary oncogenic activation of ALK (Box 2). ALK phosphorylation results in activation of downstream signalling pathways including JAK/STAT, PI3K/AKT, and MEK/ERK, which can promote cell proliferation, differentiation, and provide antiapoptotic signals. 89 when crizotinib-treated patients were retrospectively compared with matched crizotinib-naive controls, the 1-year and 2-year survival rates significantly favoured the crizotinib-treated group (70% versus 44% and 55% versus 12%, respectively; P = 0.004). 36 
Tolerability in single-arm studies
Although up to 96% of ALK+ NSCLC patients in the early studies of crizotinib reported treatment-related adverse events, the majority of these were only grade 1 or 2 in severity (Table 1) . 4, 5, 49 Given the role of ALK in the development of the visual system and gut, it is tempting to speculate that several of the common adverse effects reflect direct anti-ALK effects on the native protein.
Peripheral oedema may be a notable exception, as this adverse effect has also been described with MET inhibition. 50 The visual disturbances associated with crizotinib usually commence within days of starting the drug and involve brief light trails, flashes or image persistence occurring at the edges of the visual field. Most commonly, these occur in association with changes in lighting. Studies in rats have demonstrated that crizotinib causes significant reductions in the rate of retinal dark adaptation, but not the ability to achieve full dark adaptation, offering a partial explanation for these clinical findings. 51 Severe side effects associated with crizotinib are rare (Box 4). 4, 5, 49 Drug holidays, followed by rechallenge at a lower dose have been reported to allow ongoing treatment in some cases of severe neutropenia or transaminitis, but permanent drug discontinuation is occasionally required. 4, 49 Rapid onset hypogonadism in the majority of male patients taking crizotinib has now been reported, suggesting that serum testosterone levels should be routinely checked and replaced as appropriate during therapy. 52 Cases of crizotinib-induced asymptomatic profound brady cardia have also been described recently, the clinical significance of which remains uncertain. 53 
Future challenges
Newer ALK-directed therapies Given the early successes of crizotinib for treating ALK+ NSCLC, in terms of both activity and tolerability, it may seem strange to even consider the need for newer ALK-directed therapies in this disease. However, several opportunities present themselves as suitable for improvement. For example, despite crizotinib having a half life of over 50 h, it is administered twice a day primarily to abrogate C max -related adverse effects that occurred within the phase I study. 4, 54 Consequently, re-exploring crizotinib or exploring another ALK inhibitor as a once-daily regimen may be attractive to many patients. Although crizotinib is relatively well tolerated, it is not yet clear which of its adverse effects reflect activity against native ALK as opposed to other molecular targets (Tables 1, 2 and Box 4). Therefore, newer ALK inhibitors with narrower or different spectra of activity might offer different and, in some cases more-desirable, adverse-effect profiles. However, the dominant reason to consider newer ALKdirected therapies is to address the challenge of intrinsic and acquired resistance to crizotinib in patients with ALK+ NSCLC.
Resistance to crizotinib in the CNS Despite the dramatic activity of crizotinib in ALK+ NSCLC, the disease will eventually progress in all cases. While on many occasions resistance to crizotinib will be manifested as systemic progression, in some situations only progression of the central nervous system (CNS) occurs. 49 Accurate details on the exact proportion of times this occurs are lacking because standardized baseline and surveillance scans of the CNS were not part of any of the crizotinib trials conducted to date. Whether CNS progression represents the chance location of a change in the dominant biology of ALK+ NSCLC and/or unaffected growth secondary to relative under exposure to the drug in the CNS is uncertain. However, in one patient with CNS progression, cerebrospinal fluid drug levels were noted to be <0.3% of those seen in the blood, levels predicted to be too low to be effective against any 26 Within the initial crizotinib studies, all patients were proven to be ALK+ using the Vysis break-apart FISH probe set and it was this technology that was filed as a companion diagnostic by the FDA. 4, 5 In break-apart testing, the FISH probes flank the common breakpoint in ALK and separate when a rearrangement occurs. 25 However, several other techniques, notably immunohistochemistry and reverse-transcription PCR, are being developed. Each technique has both pros and cons. 97, 98 Whether physicians or payers in the USA and in other countries will restrict prescribing only to those proven to be ALK+ using a specific methodology, or whether prescribing in cases proven to be ALK+ by any technique will occur remains to be seen. In addition, as ALK positivity only occurs in a small proportion of NSCLC and testing resources may be limited, various screening strategies to determine who to test have also been proposed. 26 These range from clinical enrichment using the factors associated with ALK positivity listed in Box 1, to tiered molecular testing. 25, 99 In tiered testing, the most common molecular abnormality in NSCLC is assessed first and then, if negative, the next-most-common marker is assessed, until a positive result is achieved. Much of the basis for adopting or not adopting any given technique will be its sensitivity and specificity, its reproducibility over time and between centres and its cost when optimized for performance and reproducibility. The basis for adopting any given screening strategy will be based on balancing the cost savings in terms of reducing the absolute numbers of patients screened and the cost per positive within an enriched population, and the number of true positives missed by any pre-selection approach. 27 Abbreviations: ALK+, ALK-positive; FISH, fluorescence in situ hybridization; NSCLC, non-smallcell lung cancer.
ALK-fusion proteins present. 55 Further exploration of the potential for CNS progression to reflect a condition when local CNS treatment, such as radiation therapy, should be combined with ongoing use of crizotinib to continue to suppress systemic disease is warranted. In addition, if relative underexposure of the CNS to crizotinib does underlie some aspects of resistance, the potential for intrathecal delivery of crizotinib and formal assessment of meaningful CNS exposure with newer ALK-directed therapies should be considered as a means of assessing this potentially distinct mechanism of 'acquired' resistance to crizotinib.
Systemic resistance to crizotinib
Biological drug resistance, whether acquired or intrinsic, poses a significant challenge to oncogene-targeted therapy. Based on the previous paradigm of EGFRmutant NSCLC, kinase domain mutations were expected to provide a mechanism of resistance to crizotinib in ALK+ NSCLC. In fact, the first published report of the clinical activity of crizotinib was accompanied by a case report of acquired resistance secondary to two new kinase domain mutations, L1196M and C1156Y, each occurring in different clones from the same patient. 4, 56 The L1196M substitution occurs at the gatekeeper position, homologous to the T790M substitution in EGFR or the T315I substitutions in BCR-ABL. 57, 58 Five additional ALK kinase domain mutations (L1152R, G1269A, S1206Y, G1202R and 1151Tins) have since been reported from NSCLC patients with crizotinib resistance, 59 -61 with several others, including D1203N and F1174C, already identified (R. C. Doebele, unpublished data). Multiple other mutations that confer crizotinib resistance can be generated through in vitro mutagenesis screens on EML4-ALK-positive cell lines. 62, 63 Of note, one of these, F1174L, has now been identified in a patient with ALK+ inflammatory myofibroblastic tumour, harbouring a RANBP2-ALK translocation who developed crizotinib resistance.
64 F1174L is also a known activating mutation of full-length ALK in neuroblastoma. 17, 18 Increases in our understanding of crizotinib resistance mechanisms in ALK+ disease are therefore likely to be important across histologically diverse tumours.
Collectively, the available clinical and preclinical data suggest multiple different kinase mutations occurring at comparable frequencies may generate crizotinib resistance. This finding is in contrast to the EGFR paradigm where T790M predominates and other EGFR TKI resistance mutations occur only rarely. [65] [66] [67] Crizotinib mutations that cause resistance seem to be more analogous to the broad spectrum of mutations observed in BCR-ABL following treatment with imatinib. 68 Potentially, the ability of EGFR to tolerate additional mutations in its kinase domain may be constrained by the presence of the common activating mutations. 69 As EML4-ALK, similar to BCR-ABL, is not activated via mutations, the kinase domain may be less constrained and able to tolerate multiple different new mutations that impair crizotinib binding without significantly impacting the underlying activity of the kinase (Figure 2) .
In support of this hypothesis, several groups have demon strated that ALK gene rearrangements causing resistance mutations enhance the growth of cells compared with unmutated ALK rearrangements. 60, 64 By contrast, a secondary T790M mutation reduces the growth of EGFR mutant cells. 70 This could have important clinical implications for ALK+ patients. Whereas the less 'fit' T790M clones may be competed out by re-emerging sensi tive subclones in the absence of an EGFR TKI, crizotinib-resistant ALK-mutated clones may not regress so easily in the absence of an ALK TKI. Rapid onset low testosterone in men Common
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The different ALK mutations identified thus far show variability in their sensitivity to crizotinib and to other ALK inhibitors suggesting that a single nextgeneration ALK inhibitor may not be able to effectively inhibit the entire spectrum of resistance mutations. [61] [62] [63] Complicating this strategy further is the possibility of intrapatient heterogeneity in terms of different resistance mutations. 56 In a patient with mutated BCR-ABL, up to 10 different resistance mutations have been detected using mass spectrometry following progression on imatinib; comparable analyses may reveal further complexity in ALK+ disease after crizotinib therapy (Figure 2) . 72 If marked differences in systemic and CNS exposure of crizotinib and newer ALK-directed drugs occur, variation in achievable exposures might suppress some mutations, but allow others to grow in different parts of the body of the same individual with the exact patterns seen being dependant on the specific drug involved. Copy number gain of the ALK gene fusion, either alone or in combination with a kinase domain mutation, has also been observed both in vitro and in patients as an additional mechanism of crizotinib resistance. 60, 61, 73 Approximately 13% of patients with an ALK gene fusion in their pre-crizotinib sample demonstrate the presence of an additional mutated oncogene in the same sample, specifically EGFR, KRAS, BRAF or MET. 74 Potentially, selection of these or other alternate means of oncogene activation could provide a mechanism of resistance to ALK inhibitors distinct from ALK kinase domain mutations and ALK copy number gain. Of note, MET is unlikely to function as a driver of resistance to crizotinib as it is a target of the same drug; however, it could act as a driver of resistance for other non-MET directed ALK inhibitors. In DFC1032, a cell line derived from a patient with ALK+, treatment-naive NSCLC, both an ALK gene rearrangement and activation of EGFR and HER2 were noted. 75 In another cell line, derived from a patient with acquired resistance to crizotinib (DFC1076) both an L1152R resistance mutation in ALK and enhanced baseline EGFR and MET phosphorylation were noted. 59 No HER family copy number gain or mutations were detected and ligandmediated activation of a second driver pathway was therefore proposed as contributing to crizotinib resistance in both cases. In both cell lines, growth inhibition by the combination of crizotinib and an irreversible inhibitor of EGFR and HER2 was more effective than either treatment alone. 59, 75 More recently, three of 11 ALK+ patients with resistance to crizotinib were shown to have a detectable EGFR mutation or a KRAS mutation in their post-crizotinib specimen. 60 The presence of different oncogenes in the same or subsequent biopsies We hypothesize that activating mutations, such as those found in EGFR, constrain the resistance mutations to those that allow constitutive activation. In situations where activation of the kinase is driven by dimerisation via a genefusion partner (for example, BCR-ABL and EML4-ALK), the kinase domain is less constrained and can accommodate a wider array of mutations. The gatekeeper mutation, which sits at a critical position in the ATP or kinase inhibitor pocket, in each oncogene is enclosed with a box. The predominant resistance mutation in EGFR following therapy with erlotinib or gefitinib is T790M with only rare reports of other resistance mutations. [65] [66] [67] The most common resistance mutations in BCR-ABL are shown. 90 T315I, the most frequent of these, only occurs <15% of the time. The true prevalence of the different ALK mutations that produce resistance to crizotinib in patients is still unknown but a single dominant form comparable to the status of T790M does not seem apparent among the patients studied to date. 56, 60, 64, 61 Almost all of the resistance mutations found in patients have also been identified using in vitro screens. 62, 63 Additional resistant mutations identified through these screens but not yet identified in patients are shown in blue. The asterisk denotes a mutation, F1174L, which was found in an inflammatory myofibroblastic tumour with the RANB2-ALK gene fusion following crizotinib treatment; all other mutations were found in ALK-positive NSCLC patients. 64 could represent either direct mechanisms of resistance occurring within the same cells (second drivers), or the emergence of independent or divergent clones with separate drivers (Figure 3) . Certainly, introduction of a mutated EGFR cDNA can induce crizotinib resistance in an ALK+ cell line, consistent with the possibility that an EGFR mutation can act as a second driver. 59 By contrast, expression of a mutant KRAS cDNA into an ALK+ cell line did not induce resistance, raising questions about the ability of KRAS to function as a true second driver in this setting. 60 An explanation for this preclinical finding may lie in previous work demonstrating that activated KRAS does not always behave as a classical driver oncogene and its role in oncogenesis may be highly contextual. 76 In terms of direct evidence of separate drivers, in a cell line derived from an ALK+ patient at the time of progression who received crizotinib, only a KRAS mutation was detectable without evidence of a persisting ALK gene rearrangement, suggesting that two separate clonal populations each with a separate driver co-existed in the same patient. 60 Case reports of patients demonstrating both ALK positivity and an EGFR mutation who have responded to an EGFR TKI alone, rather than requiring a combination of drugs, also suggest separate drug sensitive clonal populations can co-exist in ALK+ patients. 77 Recently, amplification of the KIT gene has been reported as an additional alternate oncogene that may drive resistance to crizotinib in selected cases. 61 KIT amplification (defined as a ratio of the KIT gene to centromere 4 of >5) was noted in two of 18 cases of acquired resistance to crizotinib (one focally and one diffusely within the tumour), with accompanying preclinical evidence of the potential for KIT copy number gain to drive crizotinib resistance as a second driver in the presence of its cognate ligand stem cell factor. 61 From the resistance data collected, it seems that systemic resistance to crizotinib in ALK+ NSCLC can be divided into two groups, those that are still dominated by ALK signalling (kinase mutation and copy number gain) and those that are only partially dependent on, or independent of, ALK signalling (presence of a second or separate oncogene driver; Figure 3 ). Based on one of the largest series to date, the sizes of these two groups may be approximately equal. 60 However, given that clinical and preclinical examples positive for both kinase domain mutations and evidence of second or separate drivers have now been described, it is important to recog nise that multiple different resistance mechanisms may be generated and co-exist at different levels in the same crizotinibresistant patient. 59, 61 Next-generation ALK inhibitors alone, unless they also target other rele vant kinases, may overcome some resistance mutations or copy number gain through higher exposures and/or higher potency, but are unlikely to overcome resistance acquired through second or separate drivers. 60, 62 In such cases, combination therapy may be required. 59, 75 Of note, while the technology for detecting mutations or copy number gain is well established, identifying those who require specific Crizotinib resistance can be classified into two broad categories, those mechanisms that retain the dominance of ALK signalling and those that lose the dominance of ALK signalling either partially or completely. ALK-dominant resistance can occur through kinase domain mutations that inhibit crizotinib binding but permit ongoing constitutive activation of ALK. 56, 60, 64 ALK dominant resistance also occurs through copy number gain of the ALK gene fusion, which may co-exist with resistance mutations. 60, 73 Finally, poor penetration of crizotinib into the central nervous system (CNS) may simply allow unaltered ALK-positive cancer cells to grow because of inadequate local drug exposures. 55 For resistance that decreases the dominance of ALK signalling, a second oncogene may become active via mutation or another mechanism co-existing with oncogenic ALK in the same cells. [59] [60] [61] 73 Alternatively, true ALK-independent resistance may arise through the outgrowth of clones that do not harbour an ALK gene fusion and contain a separate activated oncogene. 60 combinations based on increased signalling of an alternate oncogene alone, as observed in the DFC1032 and DFC1076 cell-line data, is not yet feasible for routine clinical samples. For example, in a recent study that assessed phospho-EGFR levels by immuno histochemistry in paired samples taken pre-acquired resistance and postacquired resistance to crizotinib, although the study reported four of nine cases with subjectively increased staining (as evidence of EGFR pathway activation) as a potential mechanism of resistance, phospho-EGFR levels also went down in two cases. 61 Although the increased levels are intriguing and consistent with preclinical evidence, several other factors, including intratumoural heterogeneity, differences in sample fixation and preparation methodology (given the well-known lability of phosphoepitopes) and the intra-observer and inter-observer variation in immunohistochemistry quantisation might also have influenced changes in phospho-EGFR levels within the study. 61 
Other drug classes for resistant disease
Two other pharmacological classes of agent are being actively explored for their activity in crizotinib-resistant ALK+ NSCLC: pemetrexed and HSP90 inhibitors. However, just as with the new ALK inhibitors, recognising that different biological mechanisms of crizotinib resistance exist is likely to have a major impact on the development of these agents in this setting. Currently, the activity of pemetrexed has been demonstrated in ALK+ crizotinib-naive patients, but not in patients resistant to crizotinib. 39, 40 It is also not yet clear whether ALK positivity is simply associated with pemetrexed sensitivity, or whether ALK signalling per se drives that sensitivity. If the latter is correct, then mechanisms of resistance that preserve aspects of ALK signalling might retain marked sensitivity to pemetrexed, while if resistance is through the emergence of ALK-negative clones, pemetrexed may be less effective.
An alternate strategy for overcoming ALK resistance is to target the chaperone pathway. HSP90 is a chaperonin that stabilizes proteins during their maturation within the cell. 78 Multiple different oncogenic proteins have been described as potential clients for HSP90; however, not all of them are equally dependent on HSP90. ALKfusion proteins were first described as highly sensitive to HSP90 inhibition in preclinical models of NPM-ALK. 79 Subsequently, EML4-ALK was also shown to be highly sensitive to HSP90 inhibition both in vitro and in crizotinib-naive patients. [80] [81] [82] Unfortunately, with regard to their activity in crizotinib-resistant disease, two such patients have already been noted to have disease progression with HSP90 inhibitor therapy without evidence of a benefit. 82 However, it is important to note that, although HSP90 inhibitors have been shown to have activity across EML4-ALK-positive cell lines harbouring a range of different crizotinib resistance mutations, suggesting their clinical spectrum of activity may be broader than some specific ALK inhibitors in this context, the mechanism of crizotinib resistance had not been explored in either of the two patients described. 61, 73 Similar to pemetrexed, it is likely that different mechanisms of resistance to crizotinib will result in retained or reduced sensitivity to HSP90 inhibitors compared to a crizotinib-naive ALK+ population. Whether effective levels of pemetrexed or HSP90 inhibitors will penetrate the CNS with regard to patients with ALK+ brain metastases is unknown. Similarly, what biological mechanisms and how easily they will occur as a means of generating acquired resistance to these different classes of drugs in the post-crizotinib setting is also currently unknown. 83 
Local therapy for local progression
Even in situations where the mechanism of resistance is unknown or without an obvious drug-based therapy to direct towards it, resistant disease may sometimes be amenable to local therapy, such as stereotactic body radiation therapy. The logic behind this approach is that if resistance arises clonally, in conjunction with careful CT or PET-CT observation, isolated areas of growth may be identified and removed prior to more widespread dissemination of the resistant disease. [84] [85] [86] Within the phase I study of crizotinib, 37 patients continued to receive crizotinib for >2 weeks post-progression at the investigator's discretion, and 11 patients received the drug for more than 6 months from the time of their initial protocoldefined progression. 49 Although no formal details are available, in many cases this continuation likely occurred after areas of localised progression in both the body and/ or CNS were treated with radio therapy. How we formalize the definition of 'ongoing clinical benefit' to determine the true utility of attempted clonal deletion and continuing crizotinib in this setting will be yet another challenge in the future for determining the optimal manage ment of ALK+ disease.
Conclusions
ALK+ disease has emerged as a relevant clinical subtype of NSCLC based on its dramatic and prolonged benefit from crizotinib. With increased experience, key features associated with the disease are now being revealed (Box 2). The greatest challenges associated with optimally treating this disease in the future will include identifying and managing the adverse effects associated with therapy (Tables 1, 2 and Box 4), determining which of these adverse effects are likely to be class specific in light of new ALK-directed treatments being developed, and addressing the multiple different ways in which ALK+ disease may become resistant to crizotinib (Figure 3 ).
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